ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer. Materials and methods: There were 133 (82 (62%) male and 51 (38%) female) consecutive patients with a median age of 70 (64-74) years who underwent palliative treatment due to the advanced stage of oncological gastrointestinal tract disease between 2022-2024 at the Clinical Oncology and Immuno-Oncology Department. After propensity score matching, 83 (52 (63%) males) colorectal cancer (CRC) patients with a median age of 69 (64-74) years were enrolled in the retrospective analysis. The chemotherapy was based on computed tomography (CT) imaging confirming the end-stage cancer disease. Results: The multivariable model revealed chemotherapy combined with anti-epidermal growth factors receptor drug (EGFR-CTH) as the lone predictive factor for metastasis regression [odds ratio (OR): 3.59, 95% confidence interval (CI): 1.18-10.91, p = 0.024]. The receiver operating characteristic curve revealed a predictive value of EGFR-CTH with the area under the curve of 0.663, yielding a sensitivity of 58.1%, specificity of 72.5%, and precision of 0.694. Conclusions: The EGFR-CTH protocol can be regarded as an effective palliative therapy for terminal colon and rectal cancer disease. The EGFR-CTH protocol contributes to 3.6 times higher probability of CT-proven tumor regression within three months of treatment. Large-volume studies are required to confirm the outcomes presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.